OQP Participates in Bio Investment Conference... Presents Global Phase 3 Clinical Progress of 'Oregobomab'

[Asia Economy Reporter Jang Hyowon] OncoQuest Pharmaceuticals (OQP), conducting global Phase 3 clinical trials of the ovarian cancer immuno-oncology drug Oregovomab, announced on the 30th that it will participate in the '2020 Korea Bio Investment Conference' (KBIC 2020) held on November 4-5 to present the progress of Oregovomab's clinical trials.

KBIC 2020 is an event jointly hosted by the Korea Economic Daily and government agencies such as the Ministry of Science and ICT to promote the development and investment activation of the bio healthcare industry. It will be held at the Grand Ballroom of Seoul Dragon City from November 4 to 5, with 100 leading domestic bio healthcare companies participating.

About 800 attendees including fund managers, analysts, venture capitalists, angel investors, and individual investors will attend the event, which aims to explore new growth engines for the K-bio industry, whose status has risen after the COVID-19 pandemic, and to facilitate the discovery of hidden stars and networking among investors.

At the bio investment conference, OQP will present the company introduction along with the progress of the global Phase 3 clinical trial of the ovarian cancer immuno-oncology drug Oregovomab. The keynote presentation will be delivered by OQP Vice President Hwang Ji-young, a former bio analyst.

OQP's ovarian cancer immuno-oncology drug Oregovomab targets improving treatment efficacy when combined with existing chemotherapy agents paclitaxel and carboplatin. IQVIA, the world's No. 1 contract research organization (CRO), is conducting global Phase 3 clinical trials involving 602 patients across 17 countries including the United States.

Additionally, in Korea, on October 7, the K-MASTER Project Group (Precision Medicine-based Cancer Diagnosis and Treatment Development Project Group) of Korea University Medical Center received approval from the Ministry of Food and Drug Safety for Phase 1/2 clinical trials studying the safety and efficacy of combination therapy using Oregovomab and Roche’s Avastin (active ingredient bevacizumab). Patient enrollment is being prepared at Seoul Asan Medical Center and Catholic St. Mary’s Hospital.